We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Kicks Off Review of BLA for Chinese PD-1 Inhibitor
FDA Kicks Off Review of BLA for Chinese PD-1 Inhibitor
The FDA has begun its review of Innovent Biologics’ and Eli Lilly’s biologics license application (BLA) for sintilimab, a PD-1 inhibitor for the first-line treatment of nonsquamous nonsmall-cell lung cancer (NSCLC) alongside chemotherapy.